Technical Analysis for INBX - Inhibrx, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 16.29 | 1.18% | 0.19 |
Earnings due: Nov 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Shooting Star Candlestick | Bearish | 1.18% | |
New Uptrend | Bullish | 1.18% | |
Upper Bollinger Band Touch | Strength | 1.18% | |
Crossed Above 20 DMA | Bullish | 1.81% | |
Gapped Up | Strength | 1.81% | |
20 DMA Resistance | Bearish | 5.99% |
Alert | Time |
---|---|
Possible NR7 | about 14 hours ago |
Rose Above Previous Day's High | about 16 hours ago |
Up 2% | about 16 hours ago |
Upper Bollinger Band Resistance | about 17 hours ago |
60 Minute Opening Range Breakout | about 17 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 18.95 |
52 Week Low | 10.8 |
Average Volume | 96,388 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 15.45 |
20-Day Moving Average | 15.67 |
10-Day Moving Average | 15.84 |
Average True Range | 0.62 |
RSI (14) | 58.68 |
ADX | 25.82 |
+DI | 25.94 |
-DI | 12.68 |
Chandelier Exit (Long, 3 ATRs) | 15.15 |
Chandelier Exit (Short, 3 ATRs) | 16.54 |
Upper Bollinger Bands | 16.47 |
Lower Bollinger Band | 14.88 |
Percent B (%b) | 0.89 |
BandWidth | 10.17 |
MACD Line | 0.16 |
MACD Signal Line | 0.14 |
MACD Histogram | 0.0196 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 16.91 | ||||
Resistance 3 (R3) | 16.89 | 16.66 | 16.80 | ||
Resistance 2 (R2) | 16.66 | 16.50 | 16.67 | 16.77 | |
Resistance 1 (R1) | 16.48 | 16.41 | 16.57 | 16.50 | 16.73 |
Pivot Point | 16.25 | 16.25 | 16.30 | 16.26 | 16.25 |
Support 1 (S1) | 16.07 | 16.09 | 16.16 | 16.09 | 15.85 |
Support 2 (S2) | 15.84 | 16.00 | 15.85 | 15.81 | |
Support 3 (S3) | 15.66 | 15.84 | 15.78 | ||
Support 4 (S4) | 15.68 |